达格列净治疗慢性肾脏病的研究进展

摘要/Abstract

摘要：

达格列净是钠?葡萄糖共转运蛋白2抑制剂（sodium-glucose transporter 2 inhibitors，SGLT-2i）类较新型降糖药，通过促进尿糖排出以降低血糖。我国慢性肾脏病（chronic kidney disease，CKD）患者众多，且治疗手段有限。达格列净不仅是一种良好的降糖药物，同时还能减少心血管不良事件，延缓糖尿病肾病（diabetic nephropathies，DN）的发病，在非糖尿病肾病的CKD患者也观察到肾脏获益。本文旨在总结达格列净在CKD治疗中的研究进展，探讨其可能的作用机制及安全性，为临床治疗提供指导。

关键词:达格列净,SGLT-2抑制剂,糖尿病肾病,慢性肾脏病,作用机制

Abstract:

Dapagliflozin is a newer type of hypoglycemic agent of sodium-glucose transporter 2 inhibitors （SGLT-2i）， which lowers blood sugar by promoting the excretion of urine sugar. There is a large population of chronic kidney disease （CKD） in China， and the treatment options are limited. Dapagliflozin is not only a good hypoglycemic drug， but it can also reduce adverse cardiovascular events and delay diabetic nephropathies （DN）. Renal benefits have also been observed in CKD patients with non-diabetic nephropathy. This article intends to summarize the research progress of dapagliflozin in the treatment of CKD， explore its possible mechanism of action and safety and provide guidance for clinical treatment.

Key words:dapagliflozin,sodium-glucose transporter 2 inhibitors,diabetic nephropathies,chronic kidney disease,pharmacology

张青青, 刘珊珊, 王英惠, 柳刚. 达格列净治疗慢性肾脏病的研究进展[J]. betway必威登陆网址（betway.com ）学报, 2022, 43(5): 388-392.

Qingqing ZHANG, Shanshan LIU, Yinghui WANG, Gang LIU. Research progress of dapagliflozin in the treatment of chronic kidney disease[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2022, 43(5): 388-392.

参考文献38

1	Eleftheriadis T， Pissas G， Tsogka K， et al. A unifying model of glucotoxicity in human renal proximal tubular epithelial cells and the effect of the SGLT2 inhibitor dapagliflozin［J］. Int Urol Nephrol， 2020， 52（6）： 1179.
2	Petrie MC， Verma S， Docherty KF， et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes［J］. JAMA， 2020， 323（14）： 1353.
3	Wheeler DC， Stefánsson BV， Jongs N， et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease： a prespecified analysis from the DAPA-CKD trial［J］. Lancet Diabetes Endocrinol， 2021， 9（1）： 22.
4	Heerspink HJL， Stefánsson BV， Correa-Rotter R， et al. Dapagliflozin in patients with chronic kidney disease［J］. N Engl J Med， 2020， 383（15）： 1436.
5	Zhang LX， Long JY， Jiang WS， et al. Trends in chronic kidney disease in China［J］. N Engl J Med， 2016， 375（9）： 905.
6	Liang S， Cai GY， Chen XM. Clinical and pathological factors associated with progression of diabetic nephropathy［J］. Nephrology （Carlton）， 2017， 22（Suppl-4）： 14.
7	阳皓，谭巧灵，王岑，等. 达格列净对早期2型糖尿病肾病患者尿微量白蛋白和促炎症因子的影响［J］. 华中科技大学学报（医学版）， 2019， 48（4）： 400.
8	Dekkers CCJ， Wheeler DC， Sjöström CD， et al. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease［J］. Nephrol Dial Transplant， 2018， 33（11）： 2005.
9	Pollock C， Stefánsson B， Reyner D， et al. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease （DELIGHT）： a randomised， double-blind， placebo-controlled trial［J］. Lancet Diabetes Endocrinol， 2019， 7（6）： 429.
10	Fioretto P， Del Prato S， Buse JB， et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment （chronic kidney disease stage 3A）： the DERIVE Study［J］. Diabetes Obes Metab， 2018， 20（11）： 2532.
11	Petrykiv S， Sjöström CD， Greasley PJ， et al. Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function［J］. Clin J Am Soc Nephrol， 2017， 12（5）： 751.
12	Raji A， Xu ZJ， Lam RLH， et al. Efficacy and safety of sitagliptin compared with dapagliflozin in people ≥ 65 years old with type 2 diabetes and mild renal insufficiency［J］. Diabetes Ther， 2020， 11（10）： 2419.
13	Kinguchi S， Wakui H， Ito Y， et al. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy： the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study （Y-AIDA study）［J］. Cardiovasc Diabetol， 2019， 18（1）： 110.
14	Dekkers CCJ， Petrykiv S， Laverman GD， et al. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers［J］. Diabetes Obes Metab， 2018， 20（8）： 1988.
15	Heerspink HJL， Sjöström CD， Inzucchi SE， et al. Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers［J］. Diabetes Obes Metab， 2019， 21（3）： 720.
16	Fadini GP， Solini A， Manca ML， et al. Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world： a multicentre retrospective study［J］. Diabetes Obes Metab， 2019， 21（2）： 252.
17	Van Bommel EJM， Muskiet MHA， Van Baar MJB， et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized， double-blind RED trial［J］. Kidney Int， 2020， 97（1）： 202.
18	Van der Linden N， Van Olst S， Nekeman S， et al. The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands［J］. Diabet Med， 2021， 38（4）： e14371.
19	Deerochanawong C， Vareesangthip K， Piyayotai D， et al. Cost-utility analysis of dapagliflozin as an add-on to standard treatment for patients with type 2 diabetes and high risk of cardiovascular disease in Thailand［J］. Diabetes Ther， 2021， 12（7）： 1947.
20	Mathieu C， Rudofsky G， Phillip M， et al. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes （the DEPICT-2 study）： 52-week results from a randomized controlled trial［J］. Diabetes Obes Metab， 2020， 22（9）： 1516.
21	Groop PH， Dandona P， Phillip M， et al. Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes： post-hoc renal analysis of the DEPICT randomised controlled trials［J］. Lancet Diabetes Endocrinol， 2020， 8（10）： 845.
22	Cherney DZI， Dekkers CCJ， Barbour SJ， et al. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease （DIAMOND）： a randomised， double-blind， crossover trial［J］. Lancet Diabetes Endocrinol， 2020， 8（7）： 582.
23	Wheeler DC， Toto RD， Stefánsson BV， et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy［J］. Kidney Int， 2021， 100（1）： 215.
24	Rajasekeran H， Reich HN， Hladunewich MA， et al. Dapagliflozin in focal segmental glomerulosclerosis： a combined human-rodent pilot study［J］. Am J Physiol Renal Physiol， 2018， 314（3）： F412.
25	Wheeler DC， Stefansson BV， Batiushin M， et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease （DAPA-CKD） trial： baseline characteristics［J］. Nephrol Dial Transplant， 2020， 35（10）： 1700.
26	Chertow GM， Vart P， Jongs N， et al. Effects of dapagliflozin in stage 4 chronic kidney disease［J］. J Am Soc Nephrol， 2021， 32（9）： 2352.
27	Kohn OF. In CKD， the effect of dapagliflozin on kidney outcomes did not vary by T2DM status or CKD cause［J］. Ann Intern Med， 2021， 174（5）： JC53.
28	徐鲁斌，田东丽，陈丽萌. 钠糖转运子2抑制剂在糖尿病肾病管球反馈调节中的作用［J］. 中华肾脏病杂志， 2018， 34（6）： 467.
29	Yao D， Wang SY， Wang M， et al. Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1‑receptor for advanced glycation end products‑nuclear factor‑κB signaling pathway［J］. Mol Med Rep， 2018， 18（4）： 3625.
30	Oraby MA， El-Yamany MF， Safar MM， et al. Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats［J］. Biomed Pharmacother， 2019， 109： 910.
31	Huang FJ， Zhao YY， Wang QZ， et al. Dapagliflozin attenuates renal tubulointerstitial fibrosis associated with type 1 diabetes by regulating STAT1/TGFβ1 signaling［J］. Front Endocrinol （Lausanne）， 2019， 10： 441.
32	Hodrea J， Balogh DB， Hosszu A， et al. Reduced O-GlcNAcylation and tubular hypoxia contribute to the antifibrotic effect of SGLT2 inhibitor dapagliflozin in the diabetic kidney［J］. Am J Physiol Renal Physiol， 2020， 318（4）： F1017.
33	Shibusawa R， Yamada E， Okada S， et al. Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death［J］. Sci Rep， 2019， 9（1）： 9887.
34	Elkazzaz SK， Khodeer DM， El Fayoumi HM， et al. Role of Sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats； inflammation， angiogenesis and apoptosis［J］. Life Sci， 2021， 280： 119018.
35	Baer PC， Koch B， Freitag J， et al. No cytotoxic and inflammatory effects of empagliflozin and dapagliflozin on primary renal proximal tubular epithelial cells under diabetic conditionsin vitro［J］. Int J Mol Sci， 2020， 21（2）： 391.
36	Burns KD， Cherney D. Renal angiotensinogen and Sodium-Glucose cotransporter-2 inhibition： insights from experimental diabetic kidney disease［J］. Am J Nephrol， 2019， 49（4）： 328.
37	Shin SJ， Chung S， Kim SJ， et al. Effect of Sodium-Glucose Co-Transporter 2 inhibitor， dapagliflozin， on renal renin-angiotensin system in an animal model of type 2 diabetes［J］. Plos One， 2016， 11（11）： e0165703.
38	Hallow KM， Boulton DW， Penland RC， et al. Renal effects of dapagliflozin in people with and without diabetes with moderate or severe renal dysfunction： prospective modeling of an ongoing clinical trial［J］. J Pharmacol Exp Ther， 2020， 375（1）： 76.

[1]	蒋鲁杰, 王燕, 邓仰欣, 曹铭锋.微小RNA在早期糖尿病肾病中的研究进展[J]. betway必威登陆网址（betway.com ）学报, 2023, 44(6): 452-456.
[2]	杭宇昕, 于佳琦, 曹燕凤, 徐宁, 刘景林, 许良.基于网络药理学探讨蒙药翻白草治疗2型糖尿病的作用机制[J]. betway必威登陆网址（betway.com ）学报, 2023, 44(3): 191-196.
[3]	杨立芸.个体化护理在早期糖尿病肾病患者中的应用[J]. betway必威登陆网址（betway.com ）学报, 2022, 43(8): 609-613.
[4]	韩明丽, 田丹, 车欣宇, 余金毅, 肖昂, 潘国军, 肖娜.基于网络药理学研究金银花对糖尿病的作用机制[J]. betway必威登陆网址（betway.com ）学报, 2022, 43(3): 172-177.
[5]	彭茜, 蒋兰晔, 陈美英, 周燕霞.维持性血液透析左心室肥厚患者使用芪苈强心胶囊治疗后对血清FGF-23水平和心功能的影响[J]. betway必威登陆网址（betway.com ）学报, 2021, 42(8): 592-594.
[6]	赵敏, 秦树存.氢气生物医学效应的发现、研究与应用[J]. betway必威登陆网址（betway.com ）学报, 2021, 42(5): 339-346.
[7]	骆青, 孔刚.IQGAP1在2型糖尿病肾病患者足细胞凋亡中的作用探究[J]. betway必威登陆网址（betway.com ）学报, 2021, 42(4): 295-297.
[8]	许娟, 高云, 刘雯.2型糖尿病肾病患者血清25-羟维生素D水平与骨密度的相关性[J]. betway必威登陆网址（betway.com ）学报, 2021, 42(3): 190-192.